Immunosuppressive therapies for the maintenance treatment of proliferative lupus nephritis: A systematic review and network metaanalysis

Journal of Rheumatology

Volumn 42, Issue 8, 2015, Pages 1392-1400

  Tian, Simon Yu ^a,c   Feldman, Brian M ^a,b   Beyene, Joseph ^a,e   Brown, Patrick E ^a,d,e   Uleryk, Elizabeth M ^c   Silverman, Earl D ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Division of Rheumatology   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d CANCER CARE ONTARIO   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Clinical trials; Drug therapy; Immunosuppressive agents; Lupus nephritis; Metaanalysis; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; PREDNISONE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; CREATININE BLOOD LEVEL; DRUG EFFICACY; END STAGE RENAL DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; META ANALYSIS; PRIORITY JOURNAL; PROLIFERATIVE LUPUS NEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; LUPUS NEPHRITIS; REMISSION;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PREDNISONE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84940706698     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141650     Document Type: Article

References (41)

1. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95.
2. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64.
3. Benseler SM, Bargman JM, Feldman BM, Tyrrell PN, Harvey E, Hebert D, et al. Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome. Rheumatology 2009;48:176-82.
4. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:538-46.
5. Houssiau FA. Cyclophosphamide in lupus nephritis. Lupus 2005;14:53-8.
6. Costa-Reis P, Nativ S, Isgro J, Rodrigues T, Yildirim-Toruner C, Starr A, et al. Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. Clin Immunol 2013;149:442-9.
7. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004;13:673-8.
8. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
9. Hogan J, Appel GB. Update on the treatment of lupus nephritis. Curr Opin Nephrol Hypertens 2013;22:224-30.
10. Houssiau FA. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther 2012;14:202.
11. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797-808.
12. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.
13. Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84.
14. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al; MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 2010;69:2083-9.
15. Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network meta-analysis. J Rheumatol 2014;41:1998-2007.
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [Internet. Accessed April 16, 2015.] Available from: www.cochrane-handbook.org
17. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28.
18. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-94.
20. Churg J, Sobin LH. Renal disease: classification and atlas of glomerular diseases. Tokyo: Igaku-Shoin; 1982.
21. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-30.
22. Donadio JV Jr, Holley KE, Wagoner RD, Ferguson RH, McDuffie FC. Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum 1974;17:573-81.
23. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
24. Decker JL, Klippel JH, Plotz PH, Steinberg AD. Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Ann Intern Med 1975;83;606-15.
25. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: John Wiley & Sons; 2004.
26. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence: indirect treatment comparisons in meta-analysis. Canadian Agency for Drugs and Technologies in Health. [Internet. Accessed April 16, 2015.] Available from: www.cadth.ca/media/pdf/H0462-itc-tr-e.pdf
27. Spiegelhalter DJ. Incorporating Bayesian ideas into health-care evaluation. Statist Sci 2004;19:156-74.
28. Ades AE, Madan J, Welton NJ. Indirect and mixed treatment comparisons in arthritis research. Rheumatology 2011;50 Suppl 4:iv5-9.
29. Multi-Parameter Evidence Synthesis (MPES) Programme. Mixed treatment comparisons. University of Bristol. [Internet. Accessed April 16, 2015.] Available from: www.bristol.ac.uk/social-community-medicine/projects/mpes/mtc
30. Ades AE, Mavranezouli I, Dias S, Welton NJ, Whittington C, Kendall T. Network meta-analysis. International Society for Pharmacoeconomics and Outcomes Research. [Internet. Accessed April 16, 2015.] Available from: www.ispor.org/publications/value/ViHsupplementary/ViH13i8-Ades.asp
31. R Core Team. R: a language and environment for statistical computing. [Internet. Accessed April 16, 2015.] Available from: www.R-project.org
32. Sturtz S, Ligges U, Gelman A. R2WinBUGS: a package for running WinBUGS from R. J Stat Softw 2005;12:1-16.
33. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
34. Cochrane Collaboration. Review Manager (RevMan) [computer program]. Version 5.1, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2012.
35. Silverman ED, Allison EA. Systemic lupus erythematosus. In: Cassidy JT, Petty RE, Laxer RM, Lindsley C, eds. Textbook of pediatric rheumatology, 6th edition. Philadelphia: Saunders, Elsevier Inc.; 2011:315-43.
36. van Tellingen A, Voskuyl AE, Vervloet MG, Bijl M, de Sévaux RG, Berger SP, et al; Dutch Working Party on Systemic Lupus Erythematosus. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. Neth J Med 2012;70:199-206.
37. Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 2013;62:403-41.
38. Morris HK, Canetta PA, Appel GB. Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrol Dial Transplant 2013;28:1371-6.
39. Barsalou J, Levy DM, Silverman ED. An update on childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25:616-22.
40. van Vollenhoven RF. Challenges and opportunities in SLE clinical trials. Curr Opin Rheumatol 2013;25:606-15.
41. Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum 2013;65:1586-91.